About
James Barrett is a General Partner at New Enterprise Associates (NEA). He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems, and healthcare services companies. He is a director of Cardioxyl Pharmaceuticals, GlycoMimetics, Inhibitex, Nucleonics, Peptimmune, Predictive Biosciences, Proteostasis Therapeutics, Ruxton Pharmaceuticals, Sensors for Medicine and Science, Supernus Pharmaceuticals, Targacept, and Zosano Pharma. Prior to joining NEA, James Barrett served as Founder, Chairman, and CEO of Sensors for Medicine and Science, where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, President and CEO of Life Technologies, and President and CEO of Bethesda Research Labs. Previously, he worked in various divisions of GlaxoSmithKline. James Barrett received a Ph.D. in Biochemistry at the University of Tennessee, an M.B.A. from th
Position in the VCSift Database
- • 33 investors at New Enterprise Associates are tracked.
- • 6 investors hold the Partner Emeritus role in VCSift. M. James Barrett is one of them.
- • 1,381 investors are based in Washington, District of Columbia, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Washington, US
Contact Information
Find more investors like M. James
Search Investors